News

Annovis Bio’s lead investigative therapy ANVS401 (also known as Posiphen) targeting protein buildup in the brain has been granted a U.S. patent as a way of treating Parkinson’s disease, Lewy body dementia, and other Lewy body disorders. The company, previously known as QR Pharma,…

Aggregates of the Parkinson’s disease-associated protein alpha-synuclein can spread from the gut to the brain in mice, but this process is dependent on aging, likely as a result of altered protein dynamics, a new study suggests. The study, “Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology…

Scientists have uncovered a new therapeutic molecule, called BT13, that can get to the brain to boost dopamine levels — the brain chemical that’s in short supply in Parkinson’s disease — and could potentially protect against neurodegeneration. While the research is in the early stages, and the molecule…

Researchers characterized the structure and interactions of proteins connected to the leucine-rich repeat kinase 2 (LRRK2) gene, the most common genetic cause of Parkinson’s disease, opening up new avenues for the development of new treatments for the disease. The study,” Structural Basis for Rab8a Recruitment of…

Long-term treatment with Gocovri (amantadine) extended-release capsules was safe and led to sustained reductions in dyskinesia — involuntary, jerky movements — and off episodes in people with Parkinson’s disease, final data from a two-year Phase 3 clinical trial show. “As the longest-running amantadine study to date,…

RTB101, an investigational therapy being developed to treat Parkinson’s disease, is well-tolerated, can cross the blood-brain barrier, and reaches potentially therapeutic concentrations in cerebrospinal fluid (CSF), according to interim results of a Phase 1b/2a study. Developed by resTORbio, RTB101 is an orally-administered compound meant…

Oncodesign and Servier have reached the first key milestone months ahead of schedule in their partnership to develop LRRK2 inhibitors for Parkinson’s disease, the companies announced in a press release. “The collaboration works perfectly and both teams are up to the challenges,” said Philippe Genne, PhD,…

A trial in Australia will test a motion machine, called the Reviver, to understand whether it can improve balance, mobility and sensory-motor coordination in people with moderate to advanced Parkinson’s disease and atypical parkinsonism. Exercise has been shown to help ease Parkinson’s symptoms. The Reviver machine,…

Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS) has granted approval for the first in-human clinical trial of Zhittya Genesis Medicine‘s (ZGM)’s investigational therapy for Parkinson’s disease. Parkinson’s is characterized by the death of dopamine-producing neurons in the brain. A hypothesis that has gained traction in…

A majority of Parkinson’s patients in a clinical trial reported achieving a fully “on” response within 30 minutes of taking Sunovion‘s under-the-tongue apomorphine film, called APL-130277, about three months after starting its use to counter “off” episodes in this disease, a post-hoc analysis of study results…